Drug Trial Radar · NCT03737110
Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis
Last checked: Nov 20, 2026Latest source record: Sep 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
86
Actual
Start
Jan 7, 2019
Primary completion
May 29, 2020
Study completion Jun 30, 2022
Sponsor
- Lead sponsor
- Kiniksa Pharmaceuticals (UK), Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study was to assess the efficacy of rilonacept treatment in participants with recurrent pericarditis.
Conditions
- Recurrent Pericarditis
Interventions
RilonaceptDrug
Rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥12 and \<18 years old) SC , followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and \<18 years old) injections once weekly
PlaceboDrug
Placebo SC injections once weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Pericarditis Recurrence in the RW PeriodTime frame: RW Period (mean 24.8 weeks)
Locations
21 sites in 4 countries. Site status is shown where the registry gives one.
Cedars-Sinai Medical Institute
Los Angeles, California
Arthritis and Rheumatology of Georgia
Atlanta, Georgia
The Loretto Hospital
Chicago, Illinois
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota
Mayo Clinic - PPDS
Rochester, Minnesota
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Cardiology Consultants of Philadelphia
Yardley, Pennsylvania
Intermountain Healthcare
Murray, Utah
University Of Vermont Medical Center
Burlington, Vermont
Virginia Commonwealth University
Richmond, Virginia
Swedish Medical Center
Seattle, Washington
HeartCare Partners Clinical Research Unit
Milton, Queensland, Australia
GenesisCare - Cardiology Research
Doncaster East, Victoria, Australia
Bnai Zion Medical Center
Haifa, Israel
Shaare Zedek Medical Center
Jerusalem, Israel
Galilee Medical Center
Nahariya, Israel
Sheba Medical Center at Tel-Hashomer
Ramat Gan, Israel
Ospedale Pediatrico Bambino Gesù
Rome, Lazio, Italy
ASST Fatebenefratelli Sacco - Ospedale Fatebenefratelli e Oftalmico
Milan, Lombardy, Italy
Azienda Ospedaliera Città della Salute e della Scienza di Torino
Turin, Piedmont, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.